Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Slideshows|November 10, 2022
Obesity Research Roundup for Primary Care: 5 Studies At-a-Glance from ObesityWeek® 2022
Author(s)Sydney Jennings
Advertisement
Treatment options for patients with obesity have come a long way in recent years and more therapies are in development across the pharmaceutical industry. The vast majority of obesity, however, goes untreated. The Obesity Society's annual meeting, ObesityWeek® 2022, focused on ways to bridge the gap and scale up obesity treatment. Below, find briefs on 5 clinical trials presented at the meeting that may impact your clinical practice.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
2
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
3
Long-Acting Injectable HIV PrEP: Efficacy, Safety, and Injection Reactions
4
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
5